Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts

Cancer Research

Volumn 62, Issue 18, 2002, Pages 5254-5259

  Mellinghoff, Ingo K ^a   Tran, Chris ^a   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANDROGEN; PROTEIN TYROSINE KINASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; CELL DIVISION; GROWTH INHIBITORS; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037105743     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Androgen receptor signaling in androgen-refractory prostate cancer
2. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
3. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
4. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
5. Her-2-neu expression and progression toward androgen independence in human prostate cancer
6. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
7. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease
8. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
9. The epidermal growth factor receptor as a target for cancer therapy
10. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice
11. Signal characteristics of G protein-transactivated EGF receptor
12. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow
13. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
14. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
15. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents
16. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation
17. Down regulation of epidermal growth factor receptors: Direct demonstration of receptor degradation in human fibroblasts
18. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing
19. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
20. Untangling the ErbB signalling network
21. Epidermal growth factor stimulates tyrosine phosphorylation in the neonatal mouse: Association of a M(r) 55, 000 substrate with the receptor
22. Immunostaining for activated extracellular signal-regulated kinases in cells and tissues
23. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
24. Immunohistochemical demonstration of phospho-akt in high Gleason grade prostate cancer
25. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms
26. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
27. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
28. Activation of mitogen-activated protein kinase associated with prostate cancer progression
29. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
30. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models